Jeffrey Czyzenski, MD, FAAD: A documentary about the expression of eczema beneath my skin.
In this expert Q&A, FAAD dermatologist Jeffrey Cizenski, MD, offers his thoughts on National Eczema Awareness Month and AbbVie’s Under My Skin documentary.
Today’s hair is tomorrow’s loss: Talk to patients about hair breakage prevention
Dermatology Times Editor-in-Chief Dr. Zoe Diana Drellos delves into hair health topics like pearls and best practices for preventing hair breakage in patients.
JNJ-2113 Progress in clinical development program for plaque psoriasis and ulcerative colitis
Protagonist Therapeutics just announced that the company is eligible to receive a $60 million milestone payment for JNJ-2113 to participate in a Janssen-led clinical development program.
AnaptysBio Announces Positive Phase 3 Topline Results of Imcidolimab for GPP Flares
The BLA is expected to be submitted by the third quarter of 2024.
POLL: How often do you work with a gynecologist regarding genital skin cancer?
Click here to take this week’s skin cancer survey.
Expensive treatment and medical costs associated with advanced melanoma
The more advanced the stage of melanoma, the more expensive it is to treat, especially due to the rising cost of treatment.
From awareness to action: enhancing patient care
The October issue is Dermatology Times We highlight numerous awareness campaigns and their impact on improving and enhancing patient care.
American Eczema Association receives grant from CDC for AD project
The grant will support the group’s project, “Atopic dermatitis is more than just a skin disease: Raising awareness and improving care.”
Supporting the mental health needs of dermatology patients
This World Mental Health Day, Dermatology Times looks at the important and often comorbid mental health issues associated with common skin conditions.
Advances in the diagnosis and treatment of atopic dermatitis in the elderly
Alzheimer’s disease in older adults requires specialized attention, taking into account the unique challenges posed by co-occurring skin diseases and underlying systemic diseases.
Portela’s Tips: Dealing with blackheads and whiteheads
This week on Pointers With Portela, 208SkinDoc reviews tips and product recommendations for treating blackheads and whiteheads.
Reduced mortality associated with vitiligo
Because there is limited information about the risk of mortality in patients with vitiligo, researchers investigated mortality rates in vitiligo in a population-based cohort study.
Dermatologists’ heated debate: Stagnation and change
Dr. Zoe Diana Drellos, who attended this year’s World Mental Health Day, discusses the importance of prioritizing physician health to prevent burnout, or “stasis” in Drellos’ words.
Finding balance in a busy conference season
Dr. Christina Collins details the importance of being present in the moments you can control and prioritizing self-care while on the go.
Journal Digest: October 10th
This week’s collection of the latest dermatology research includes the incidence of keratinocyte carcinoma, upadacitinib used to treat discoid lupus erythematosus, a look at hair camouflage in black women with alopecia, and surgical treatment of congenital melanocytic nevi. The perspective of parents of infants receiving treatment is addressed.
Gut microbiota has a significant impact on atopic dermatitis
The effects begin in the womb, and the mother’s diet and health play an important role in the child’s likelihood of developing the disease.
Many considerations for the management of generalized pustular psoriasis
Experts discuss the treatment status of generalized pustular psoriasis and consider difficult cases of GPP.
New Phase 3 data on long-term efficacy of upadacitinib in atopic dermatitis presented at EADV
This data provides compelling evidence for the sustained efficacy and safety of oral JAK1 inhibitors over 140 weeks in the treatment of moderate to severe atopic dermatitis.
FDA approves IND for scleroderma treatment KYV-101
Kyverna Therapeutics is now able to begin a Phase 1/2 open-label, multicenter study of KYV-101.
Atopic dermatitis and its effects from the patient’s perspective
Dermatologist Diego Luis DaSilva, MD (FAAD) and atopic dermatitis patients talk about the patient’s journey from initial symptoms to diagnosis and treatment selection.
Sexual and Sexual Minority Patients with Chronic Inflammatory Skin Diseases Affected by Barriers to Care
Sexual and sexual minority patients with chronic inflammatory skin diseases may be disproportionately affected by cost and non-cost barriers to health care.
Research explores dermatology patient journey to enhance patient care and address unmet needs
The European Academy of Dermatology and Venereology Research investigated the pathway from dermatology consultation to diagnosis, treatment and outcomes in the health care system.
Bristol-Myers Squibb presents 3-year safety and efficacy data for deucravacitinib in PSO at EADV
The clinical response rate of PASI-75 in the POETYK PSO long-term extension study was maintained at 73.2%.
Insight Announces Positive 52-Week Data on Povolcitinib EADV for Widespread Nonsegmental Vitiligo
Long-term use of povolcitinib demonstrated further improvement in systemic and facial repigmentation.
Eric Simpson, MD discusses recently published EADV data on Tapinarov Cream for AD up to 2 years
New data for ADORING 1 and ADORING 2 show that itch relief decreases rapidly within 24 hours after initial application.
Acne aggregation: Overview and effective management strategies
The impact that acne conglomerates has on individuals highlights the important role that dermatologists play in providing effective diagnosis, treatment, and psychological support.
Interim data from positive study of Almiral reveals significant improvement in health status in psoriasis patients
Patients and their families experienced significant improvements in their health status in just 16 weeks with the use of tildrakizumab.
Upadacitinib meets primary endpoint in Phase 2 trial in vitiligo and advances to Phase 3
AbbVie presented 24-week and 52-week data at EADV 2023.
October Pipeline Preview
Aaron Ferberg, MD, and Shanna Miranti MPAS, PA-C discuss the upcoming approval of nivolumab and IDP-126.
Living with congenital pachyonychia: patient perspectives and activities
The PC Project gives patients access to the international PC research registry for clinical help for rare and painful skin diseases.
Sue Ellen Cox, MD looks ahead to Hyperhidrosis Awareness Month
November is Hyperhidrosis Awareness Month, and dermatologists are gearing up for another month of raising awareness to improve patient outcomes.
Artificial Intelligence: Friend or Foe?
This month’s cover feature delves into new applications and uses of AI in dermatology and considers how AI can support, rather than hinder, clinicians.
Arcutis presents positive data for roflumilastfoam from ARRECTOR trial in scalp and body PsO at EADV
At week 8, 65.3% of patients treated with roflumilast achieved clinically significant itch relief.
Psychodermatology: Exploring the relationship between dermatology and psychiatry in skin diseases
Last week was Repetitive Behavior Awareness Week with a focus on the body. Dermatomania, also known as skin picking disease in relation to dermatology, is a condition that requires empathy and understanding all year round.
Advantage and ADvocate study supports clinical improvement in Alzheimer’s disease with lebrikizumab
Dr. Almiral presented new data at EADV on lebrikizumab associated with clinical improvement and clinically meaningful treatment responses in patients with atopic dermatitis.
Amritelimab significantly improved mean EASI score in Phase 2b AD study
Sanofi’s Phase 3 program for amritelimab in atopic dermatitis is expected to begin in early 2024.
Bimekizumab achieved meaningful clinical improvement in hidradenitis suppurativa, according to EADV data
UCB presented data from the BE HEARD I and BE HEARD II Phase 3 trials at this year’s EADV Congress.
Trevi Therapeutics Announces New Phase 2b/3 Results for Haduvio in Prurigo Nodularis
A continued decrease in WI-NRS was seen in patients who remained in the study through week 52.
Treatment-related acne after application of ruxolitinib for vitiligo occurred in a patient with no history of acne